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Immunocompromised adults can have prolonged acute respiratory syndrome coronavirus 2
(SARS-CoV-2) positive RT-PCR results, long after the initial diagnosis of coronavirus disease
2019 (COVID-19). This study aimed to determine if SARS-CoV-2 virus can be recovered in
viral cell culture from immunocompromised adults with persistently positive SARS-CoV-2
RT-PCR tests. We obtained 20 remnant SARS-CoV-2 PCR positive nasopharyngeal swabs
from 20 immunocompromised adults with a positive RT-PCR test ≥14 days after the initial
positive test. The patients’ 2nd test samples underwent SARS-CoV-2 antigen testing, and
culture with Vero-hACE2-TMPRSS2 cells. Viral RNA and cultivable virus were recovered
from the cultured cells after qRT-PCR and plaque assays. Of 20 patients, 10 (50%) had a
solid organ transplant and 5 (25%) had a hematologic malignancy. For most patients, RTPCR Ct values increased over time. There were 2 patients with positive viral cell cultures; one
patient had chronic lymphocytic leukemia treated with venetoclax and obinutuzumab who
had a low viral titer of 27 PFU/mL. The second patient had marginal zone lymphoma treated
with bendamustine and rituximab who had a high viral titer of 2 x 106 PFU/mL. Most samples
collected ≥7 days after an initial positive SARS-CoV-2 RT-PCR had negative viral cell
cultures. The 2 patients with positive viral cell cultures had hematologic malignancies treated
with chemotherapy and B cell depleting therapy. One patient had a high concentration titer of
cultivable virus. Further data are needed to determine risk factors for persistent viral shedding
and methods to prevent SARS-CoV-2 transmission from immunocompromised hosts.
Keywords: COVID-19, SARS-CoV-2, immunocompromised, rituximab, obinutuzumab, laboratory medicine, viral
cell culture
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clinical settings at various locations across the BJH system. A
convenience sample of 20 immunocompromised patients with
eligible NP swabs were included in the analyses. These NP swab
samples were sent for antigen testing and viral cell culture.
Additional chart review was performed to collect patient
demographic data, clinical characteristics including
comorbidities, immunosuppressive medications, and duration
and severity of COVID-19 clinical illness.

INTRODUCTION
Coronavirus disease 2019 (COVID-19) was declared a public
health emergency by the World Health Organization (WHO) in
January 2020 and deemed a global pandemic in March 2020.
Detection of viral RNA using real time, reverse transcriptasepolymerase chain reaction (RT-PCR) is the gold standard
diagnostic test for SARS-CoV-2, the virus that causes COVID19. Many patients diagnosed with COVID-19 have multiple
positive repeat RT-PCR tests for SARS-CoV-2 even after
resolution of COVID-19 symptoms (Lu et al., 2020; Owusu
et al., 2021). Although replication-competent virus has not
been isolated from most immunocompetent patients with mild
symptoms after 10 days, there have been reports of persistent
shedding of replication-competent, cell culture positive SARSCoV-2 virus in immunocompromised hosts beyond 20 days
(Avanzato et al., 2020; Aydillo et al., 2020; Choi et al., 2020;
Kim et al., 2021).
Currently, CDC recommendations acknowledge that severely
immunocompromised patients may have persistent viral shedding
beyond 20 days, thus recommending consideration of infectious
disease consultation and additional testing before removing
isolation precautions (“Ending Isolation and Precautions for
People with COVID-19: Interim Guidance,” 2021). Whether or
not and how long immunocompromised patients shed infectious
virus has profound implications for understanding disease
transmission and treatment for these patients. This study aimed
to determine if SARS-CoV-2 virus could be recovered in viral cell
culture from immunocompromised adults with a repeat positive
SARS-CoV-2 RT-PCR tests ≥14 days after their ﬁrst positive RTPCR test.

Molecular Detection of SARS-CoV-2
For initial clinical RT-PCR testing, acceptable transport tubes for
the NP swabs included Universal Transport Medium (UTM) and
ESwab (with Aimes Transport Medium). Molecular testing was
performed by the BJH Clinical Laboratory and due to supply
chain issues and need for high testing volume, multiple assays
under Emergency Use Authorization by the FDA were utilized
(Raju et al., 2021). Systems utilized included the: Roche cobas
SARS-CoV-2 assay on the Roche cobas 6800 (Roche Molecular
Systems, Branchburg, NJ), Cepheid Xpert Xpress SARS-CoV-2
assay on the GeneXpert (Cepheid, Sunnyvale, CA),
BioFire Respiratory Panel 2.1 (BioFire, Salt Lake City, UT),
DiaSorin Molecular Simplexa ™ on the Liaison ® MDX
(DiaSorin, Saluggia, Italy), and Lyra SARS-CoV-2 Assay
(Quidel) on EasyMag(bioMerieux)/RotorGene Q (Qiagen) or
KingFisher (Thermoﬁsher)/Applied Biosystems 7500 Fast Dx
(Thermoﬁsher). PCR cycle time (Ct) thresholds were recorded
for all SARS-CoV-2 RT-PCR tests that were performed by the
BJH Clinical Laboratory if available. For tests that provided 2
values, the lower value was used if there was a difference of ≤3
between the 2 values; if one of the values was 0, the larger number
was used. As the Lyra assay does not include the ﬁrst 10 cycles in
the reported Ct value, a correction factor of 10 was added to all
Ct values provided by the Lyra assay (Ransom et al., 2020; Potter
et al., 2021).

METHODS
Study Design and Patient Identiﬁcation

Antigen Testing

This was a single-center, retrospective, pilot study conducted at
Barnes Jewish Hospital (BJH), a large, academic, tertiary referral
hospital in Saint Louis, MO.
The BJH medical informatics database was queried to identify
adults ≥18 years old with ≥2 positive SARS-CoV-2 RT-PCR tests
between March and December 2020. Patients were considered to
have a persistently positive result if they had a repeat positive test
≥14 days after their ﬁrst positive test. Chart review was
performed to identify which patients with ≥2 positive SARSCoV-2 RT-PCR tests were immunocompromised (current
cancer treatment, bone marrow or solid organ transplantation,
immune deﬁciencies, HIV with low CD4 count or not on
treatment, prolonged use of corticosteroids or other
immunosuppressive medications). Remnant NP swabs from
the patients’ 2nd test, which was not necessarily the RT-PCR
test that qualiﬁed the patient for inclusion in the study, were
collected from the BJH clinical microbiology laboratory; patients
were excluded if remnant NP swab samples were unavailable.
The NP swabs were all originally obtained during routine clinical
care and included outpatient, inpatient, and emergency room
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The eluate from the NP swab sample (that had been stored
frozen at -80°C) from the patients’ remnant second positive NP
swab sample was sent for antigen testing on the BD Veritor
System (BD, Franklin Lakes, NJ). Samples were vortexed for at
least 10 seconds and then a swab from the antigen testing kit was
placed in the UTM or ESwab solution. The swab was placed in
the reaction tube and swirled in the ﬂuid for at least 15 seconds.
Analysis was performed according to the manufacturer
instructions for use and the assay interpretation was obtained
from the BD Veritor analyzer.

Viral Cell Culture
Biosafety
For the viral culture, all aspects of this study were approved by
the ofﬁce of Environmental Health and Safety at Washington
University School of Medicine prior to the initiation of this
study. Work with SARS-CoV-2 was performed in a BSL-3
laboratory by vaccinated personnel equipped with powered air
purifying respirators.
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tests (including antigen and RT-PCR tests) with 18,165 positive
tests. In April, November, and December 2020 the positivity
rates were around 14-16% and 3-7% in the other months.
Demographic and clinical characteristics are presented in
Table 1. Median age at the date of the ﬁrst positive RT-PCR
test was 64 years. Ten (50%) of the patients had received a SOT
(7 with lung transplants); 5 (25%) patients had a hematologic
malignancy, including 1 (5%) patient who had received a bone
marrow transplant within 6 months prior to their COVID-19
diagnosis; and 3 (15%) patients had another condition treated
with immunosuppressive medication including 1 patient with
rheumatoid arthritis, 1 patient with polymyositis, and 1 patient
on prednisone for COPD.

Virus Outgrowth Assay
Patient samples were thawed and 250 µL from each sample was
mixed with 2.75 mL of Dulbecco’s Modiﬁed Eagle Medium
(DMEM) containing 5% heat-inactivated fetal bovine serum
(FBS), 10 mM HEPES, 1X Penicillin/Streptomycin, and
glutamine and amphotericin-B, then passed through a 0.45 µm
ﬁlter. Media-only was used as negative control and media spiked
with 1,000, 100, or 10 PFU of the 2019n-CoV/USA_WA1/2019
SARS-CoV-2 isolate were used as positive controls. Filtered
samples were inoculated into T-25 ﬂasks containing Vero cells
ectopically expressing TMPRSS2 and human ACE2 (provided by
Adrian Creanga and Barney Graham, Vaccine Research Center,
NIH) in 5 mL of cell culture media (VanBlargan et al., 2021).
Cultures were observed daily for 7 days for cytopathic effect
(CPE); cultures that displayed CPE that was inconsistent with
typical SARS-CoV-2 were passaged forward, and the original
samples were re-ﬁltered and re-inoculated using only 10 µL to
reduce cytotoxicity but maximize viral recovery. Upon
observation of syncytia formation characteristic of SARS-CoV2 CPE, culture supernatants were clariﬁed and frozen.

SARS-CoV-2 Molecular Testing, Antigen
Testing, and Viral Cell Culture
The median number of RT-PCR tests after the initial positive test
was 2 (range 1-7). The median time between the ﬁrst and second
positive RT-PCR tests was 21 days (range 7-62). PCR Ct values
for 15 of the 20 patients are shown in Figure 1; 5 patients had
RT-PCR tests performed on the BioFire assay, which does not
provide a Ct value, or had missing Ct values and were therefore
not included in the ﬁgure. There were 8 patients with increasing
Ct values over time, 3 patients with decreasing Ct values, and in 4
patients, the Ct value remained stable or only had one value
recorded. However, one patient (#1) had Ct values that initially
increased before signiﬁcantly decreasing on subsequent tests.
Of the 20 samples tested, antigen testing was positive in 6
(30%). There were 2 samples that yielded positive viral cell cultures
(Table 2). Both patients had hematologic malignancies and were
being actively treated with chemotherapy and an anti-CD20
monoclonal antibody with associated hypogammaglobulinemia.

Viral Sequencing
Viral sequencing was performed at the Washington University
McDonnell Genome Institute (Saint Louis, MO). RNA was
extracted from cell-culture supernatant using the MagMax
Viral 96 kit (ABI) on the Flex System (KingFisher). Extracted
RNA was subjected to the ARTIC deep-sequencing protocol
which was performed on a HiSeq platform (Illumina)
(doi:10.17504/protocols.io.bgxjjxkn).

Plaque Forming Assay
Vero-TMPRSS2-ACE2 cells (2.5 x 105 cells per well) were added
to ﬂat-bottom 12-well tissue culture plates. The following day,
media was removed and replaced with 200 µL of 10-fold serial
dilutions of the original patient sample in DMEM supplemented
with 2% FBS. One hour later, 1 mL of methylcellulose overlay
was added. Plates were incubated for 48 hours, then ﬁxed with
4% paraformaldehyde (ﬁnal concentration) in PBS for 20
minutes. Plates were stained with 0.05% (w/v) crystal violet in
20% methanol and washed twice with distilled, deionized H2O.

Patient Characteristics
Patient #1 was a 60 year-old man with chronic lymphocytic
leukemia (CLL) undergoing treatment with venetoclax
chemotherapy and obinutuzumab (an anti-CD20 monoclonal
antibody). He started this treatment regimen about 5 months
prior to his COVID-19 diagnosis, with the last dose of
obinutuzumab received 19 days prior to his ﬁrst positive
SARS-CoV-2 RT-PCR test. He was initially hospitalized for
management of diarrhea and tested positive for COVID-19 at
admission. He developed severe COVID-19 complicated by
septic shock, respiratory failure requiring mechanical
ventilation, acute on chronic kidney injury with initiation of
dialysis in the intensive care unit, and ultimately died from
COVID-19 at 18 weeks after diagnosis. Over a span of 4 months,
he had 7 positive SARS-CoV-2 RT-PCR tests. Between the 3rd
test (day 45 from ﬁrst positive test) and 4th test (day 66), the Ct
values increased. However, the Ct values subsequently decreased.
Viral cell culture from the day 23 sample was positive at 27
plaque forming units (PFU)/mL; he also had a positive antigen
test at this time.
Patient #2 was a 75 year-old man with marginal zone
lymphoma undergoing treatment with bendamustine
chemotherapy and rituximab (an anti-CD20 monoclonal

Statistics
Descriptive statistics were used to describe patient demographics
and clinical characteristics. PCR Ct values were plotted against
the time since the ﬁrst positive RT-PCR test. Analyses were
performed using SAS 9.4 (SAS Institute, Cary, NC).

RESULTS
Demographics
From 183 patient charts chosen for screening, 36 immunocompromised patients were identiﬁed for further chart review
until 20 patients with repeat positive tests with available NP swab
specimens were identiﬁed for inclusion in the study. From April
through December 2020, the lab performed 213,940 COVID-19
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TABLE 1 | Patient demographics.
Variable

Sex
Male
Racea
White
Black
BMI
Age at date of ﬁrst positive PCR
Time between ﬁrst and second positive PCRs (days)
Number of positive PCR tests after the initial positive test
Immunosuppressive conditionb
Solid organ transplant
Hematologic malignancy
Bone marrow transplant 6 months beforeﬁrst positive
PCR
Other
Solid organ malignancyb
Immunosuppressive medicationc
Receiving high dose steroids at time of positive PCR
test
Receiving biologic medication in prior 30 days
Receiving other immunosuppressive medication in
prior 30 days
Other comorbidities
Hypertension
Heart diseased
Chronic kidney disease
Dialysis
Chronic lung disease
Chronic obstructive pulmonary disease
Diabetes
Obesity
Current smoker
Chronic liver disease

antibody). He started this treatment regimen about 3 months
prior to COVID-19 diagnosis, with the last dose of rituximab
received 11 days prior to his ﬁrst positive RT-PCR test. He was
hospitalized for 4 days and discharged on home oxygen therapy
with daily telephone follow-up. He reported persistent fever and
shortness of breath, and his symptoms resolved around 8 weeks
after his initial COVID-19 diagnosis. Over about 3 months, he
had 8 positive RT-PCR tests. On initial repeat testing, the Ct
values increased and subsequently stabilized. The viral cell
culture from the day 22 sample was positive at 2 x 106 PFU/
mL. Notably, he had a negative antigen test at this time.
There were 2 patients with negative SARS-CoV-2 viral cell
cultures who were also being treated with rituximab around the
time of their ﬁrst positive SARS-CoV-2 RT PCR test. One patient
was a 38 year-old man with polymyositis on high dose steroids
and rituximab who presented with fevers and shortness of
breath; he last received rituximab 4 months prior to his ﬁrst
positive RT-PCR test. He underwent a 3rd RT-PCR test 4 weeks
after the second positive test due to persistent respiratory
symptoms; his symptoms and progressive ﬁbrotic pulmonary
changes were ultimately attributed to pulmonary complications
of polymyositis. The other patient was a 77 year-old woman with
CLL on venetoclax and rituximab; she received rituximab 8 days
before her ﬁrst positive RT-PCR test. She initially presented with
fevers, shortness of breath with activity, and fatigue. Her
shortness of breath lasted for 6 weeks and she had a relatively
mild clinical course. She continued to have fatigue afterwards but
did not have any additional repeat RT-PCR tests after the
second test.

All patients (N=20)
N (%) or Median
(range)

11 (55)
14 (70)
6 (30)
27.2 (20.1 – 52.0)
64 (20 – 79)
21 (7 – 62)
2 (1-7)
10 (50)
5 (25)
1 (5)
3 (15)
1 (5)
5 (25)
2 (10)
11 (55)

13 (65)
12 (60)
10 (50)
3 (15)
7 (35)
4 (20)
6 (30)
6 (30)
2 (10)
1 (5)

DISCUSSION

a

All patients were non-Hispanic.
b
The patient qualiﬁed for the study as they were on dexamethasone for >30 days prior to
the ﬁrst positive RT-PCR test.
c
Prednisone status unknown for 1 patient; autoimmune diseases status unknown for one patient.
d
Heart failure, coronary artery disease, congenital heart disease, cardiomyopathies,
pulmonary hypertension.

In this pilot study of 20 immunocompromised adults with
persistently positive SARS-CoV-2 RT-PCR tests, only 2 patients
had positive viral cell cultures detected from their 2nd positive test.
Antigen testing of the repeat sample was positive for 6 patients.

FIGURE 1 | Open symbol indicates sample was cultured.
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TABLE 2 | Characteristics of patients with a positive SARS-CoV-2 cell culture.
Variable

Patient #1

Patient #2

History at time of ﬁrst positive SARS-CoV-2 60 year old male with chronic lymphocytic leukemia who
RT-PCR
presented with cough and diarrhea.
Other medical conditions
Fibromyalgia
Hyperlipidemia
Positive SARS-CoV-2 RT-PCR tests (days
after ﬁrst positive test Day 0) (study
samples in bold)

Day 0
Day 81
Day 23
Day 111
Day 45
Day 120
Day 66

Malignancy treatment (last dose prior to
positive test)
SARS-CoV-2 antigen test
Cause of death
SARS-CoV-2 cell culture results from the
repeat test (plaque forming units/mL)
Spike protein mutations from the repeat
test

Obinutuzumab and venetoclax (Day -19)

75 year old male with marginal zone lymphoma who
presented with 2 weeks of cough.
Hyperlipidemia
Deep vein thrombosis
Acute hemolytic anemia
Day 0
Day 57
Day 22
Day 67
Day 29
Day 79
Day 36
Day 43
Bendamustine and rituximab (Day -11)

Positive
COVID-19
27 PFU/mL

Negative
Alive as of 16 months after COVID-19 diagnosis
2 x 106 PFU/mL

D614G

D614G, S98F, S813l

with positive viral cell cultures and a Ct value ≥34 associated with
negative viral cell cultures (La Scola et al., 2020). Although Ct
values have been shown to correlate with severity of SARS-CoV2 infection and have been used as a surrogate marker for viral
load for research purposes, there are many different RT-PCR
assays with different gene targets, Ct values differ between testing
platforms, and there are no standardized cutoff thresholds for
clinical interpretation (Potter et al., 2021; Rhoads et al., 2021).
The use of Ct values as a tool for COVID-19 infection
prevention purposes has been investigated previously (Bullard
et al., 2020; He et al., 2020). This is of particular interest in
immunocompromised patients as SARS-CoV-2 viral load and
transmission are likely to be more unpredictable than in
immunocompetent patients, and this may have implications
with regards to isolation precautions. Recognizing that caution
must be exercised in interpretation of Ct values to make clinical
inferences, we observed that, for the most part, Ct values increased
with subsequent tests, which is what would be expected during the
clinical course of COVID-19 and resolution. However, this was
not the case for the 2 patients with positive viral cell cultures weeks
after their initial positive RT-PCR test.
Patient #1 ultimately developed severe COVID-19 and had
multiple RT-PCR tests from the same testing platform showing a
signiﬁcant decrease in Ct values (greater viral RNA levels) while he
was clinically decompensating. His viral cell culture had a low titer
of 27 PFU/mL, but the sample was collected fairly early in his
clinical course at 23 days after his initial COVID-19 diagnosis, and
we did not test the subsequent samples to assess the trend in viral
load after this time. Antigen testing was positive in this patient
from the same sample collected at 23 days after the initial positive
RT-PCR test. In contrast, patient #2 had more moderate disease
but unexpectedly had a very high viral titer of 2 x 106 PFU/mL
from a sample obtained 22 days after his initial COVID-19
diagnosis with a negative antigen test. Although he initially

Many case reports of immunocompromised patients with
persistent COVID-19 have suggested that patients with
hematologic malignancy and treatment with B-cell depleting
therapy complicated by hypogammaglobulinemia are at
particular risk for persistent viral shedding and severe COVID19 disease (Avanzato et al., 2020; Choi et al., 2020; Fürstenau
et al., 2020). Consistent with this, the 2 patients with positive
viral cell cultures in our cohort also had hematologic
malignancies and were u ndergoing treatment with
chemotherapy and either rituximab or obinutuzumab, both of
which are monoclonal antibodies against CD20 which deplete B
cells. There were also 2 patients in this study who, despite being
on rituximab, had negative viral cell cultures. This is important
to note as it has potential implications for viral transmissibility,
management, and infection prevention measures. However,
despite this need to understand which immunocompromised
patients are at risk for continued viral shedding, there are no
routinely available tests for use in a real-time, clinical setting
to conﬁrm whether a patient has persistent shedding of
infectious virus.
SARS-CoV-2 RT-PCR tests are reported as positive or
negative, and Ct values are not reported in routine clinical
practice. Higher Ct values have been associated with lower
viral RNA concentration in a sample load, although the use of
the Ct thresholds as a clinical tool has been somewhat
controversial. Previous data from outpatient settings
demonstrated that Ct values were similar among symptomatic
and asymptomatic patients with COVID-19 (Lee et al., 2020),
but in hospitalized patients, high viral loads based on lower Ct
values at admission were associated with increased mortality
(Magleby et al., 2020; Westblade et al., 2020). An association
between Ct value and culture positivity has also been previously
observed, with Ct values of 13-15 reported from the EZ1 Virus
Mini Kit 2.0, which targets the E-gene, being highly correlated
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malignancy) and thus provides additional clinical insight.
There are several limitations to our study. This was a
retrospective pilot study with a small sample size utilizing
convenience samples. Because we only queried our institutional
database for information, we would have missed any additional
COVID-19 tests performed by facilities other than the BJH
clinical laboratory. Due to supply chain constraints and high
volume of testing needed, different SARS-CoV-2 PCR assays
were used for diagnosing COVID-19 in the clinical laboratory.
Therefore, patients in this study had results reported from
different assays, which complicates comparison of Ct values
across instruments and genes targeted in the assay (Rhoads
et al., 2021). We performed viral cell cultures at a single point
and therefore lack longitudinal data about viral load and how it
correlated with clinical status and Ct values; this is an important
topic for future investigations. This study was performed on
samples collected earlier in the pandemic and no known variants
of concern were identiﬁed; the results may differ now that the
predominant strains in the U.S. have changed.

required a short hospitalization of 4 days, he was primarily
managed as an outpatient on home oxygen for most of his
prolonged 2-month clinical course. He had an initial increase in
Ct values as expected, but the Ct values subsequently remained
stable until testing was stopped after his ﬁrst negative test at 93
days after his ﬁrst positive RT-PCR test.
In this study, only 6 out of 20 patients had a positive antigen
test on the repeat sample. Notably, the two patients with positive
viral cell cultures both had negative antigen tests. Although the
antigen tests have very good speciﬁcity near 95-100%, they have
lower analytical sensitivity compared to PCR based assays (Scohy
et al., 2020; Liu & Rusling, 2021). The BD Veritor system used
herein reports a limit of detection of 1.4 x 102 TCID50/mL, an
estimated clinical sensitivity of 84% with diminished sensitivity
after the ﬁrst ﬁve days of symptom onset, and that negative results
should be conﬁrmed with a molecular assay (https://www.bd.com/
documents/guides/directions-for-use/IDS_BD-Veritor-PlusSARS-CoV-2-500048916_DF_EN.pdf). Therefore, it is difﬁcult to
draw any inferences about the signiﬁcance of the negative antigen
tests from the patients with positive viral cell cultures.
The ﬁndings of this study support prior reports showing that
immunocompromised patients can have positive SARS-CoV-2
cell cultures beyond 20 days and that patients with hematologic
malignancies on B cell depleting therapy seem to be at
particularly increased risk (Avanzato et al., 2020; Aydillo et al.,
2020; Choi et al., 2020; Fürstenau et al., 2020). We have also
shown that the 2 patients we identiﬁed with persistent, active
COVID-19 with positive viral cell cultures did not have the
expected increase in Ct values over multiple repeat RT-PCR tests.
Although the use of Ct values is not routine in the clinical
management of patients with COVID-19, Ct values may be
useful on a case-by-case basis in high-risk patients to make
clinical decisions regarding treatment and isolation precautions.
Notably, there were also 2 patients in our cohort treated with
rituximab prior to their ﬁrst positive SARS-CoV-2 RT-PCR test
who had negative viral cell cultures from the second positive NP
swab sample. Despite having prolonged symptoms, medical
records indicate that the treating clinicians thought that these
were secondary to the patient’s underlying medical conditions
rather than persistent COVID-19 disease and they were not
subject to repeat RT-PCR testing because of this.
There were 2 patients who qualiﬁed for the study because they
had a positive RT-PCR test ≥14 days after the ﬁrst positive test.
However, their 2 nd positive tests were at days 7 and 12
respectively and these were the samples that were sent for viral
cell culture. Both of these patients had negative viral cell cultures
even though this repeat sample was collected <14 days after their
ﬁrst positive test.
When this study was conceived, there were primarily case
reports of persistent, cultivable SARS-CoV-2 virus isolated from
samples derived from immunocompromised patients. This study
used a more systematic approach to assess the question of
whether immunocompromised patients might have persistent
shedding of potentially infectious virus and included a balanced
distribution of patients with immunocompromising conditions
of interest (50% with a SOT, 25% with a hematologic
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CONCLUSION
Our ﬁndings indicate that patients with hematologic
malignancies on B-cell depleting therapy who develop COVID19 are at particular risk of having prolonged SARS-CoV-2 viral
cell culture positivity. Additional studies should be performed in
immunocompromised patients with COVID-19 to further clarify
the risk factors and features associated with persistent shedding
of potentially infectious SARS-CoV-2. Further study is also
needed to determine the best management and infection
prevention strategies for these patients.
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